Anxiety in Children Undergoing VCUG: Sedation or No Sedation?

David W. Herd

Department of Paediatrics, Starship Children’s Hospital, University of Auckland, Private Bag 92024, Auckland, New Zealand

Correspondence should be addressed to David W. Herd, david.herd@mac.com

Received 9 January 2008; Accepted 14 May 2008

Recommended by Walid A. Farhat

Background. Voiding cystourethograms are distressing for children and parents. Nonpharmacological methods reduce distress. Pharmacological interventions for VCUG focus on sedation as well as analgesia, anxiolysis, and amnesia. Sedation has cost, time, and safety issues. Which agents and route should we use? Are we sure that sedation does not influence the ability to diagnose vesicoureteric reflux? Methods. Literature search of Medline, EMBASE, and the Cochrane Database. Review of comparative studies found. Results. Seven comparative studies including two randomised controlled trials were reviewed. Midazolam given orally (0.5–0.6 mg/kg) or intranasally (0.2 mg/kg) is effective with no apparent effect on voiding dynamics. Insufficient evidence to recommend other sedating agents was found. Deeper sedating agents may interfere with voiding dynamics. Conclusion. Midazolam reduces the VCUG distress, causes amnesia, and does not appear to interfere with voiding dynamics. Midazolam combined with simple analgesia is an effective method to reduce distress to children undergoing VCUG.

Copyright © 2008 David W. Herd. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The voiding cystourethrogram (VCUG) is the gold standard for diagnosing vesicoureteric reflux (VUR) and a number of other bladder conditions [1, 2]. The VCUG is a procedure performed mainly on infants and young children in the Radiology Department [3]. There is increasing belief that interventions for VUR are less effective than anticipated, but much debate remains [4–11]. The child is required to be conscious, a urinary catheter is inserted, and the bladder is filled with radio-opaque material, then the child is asked to spontaneously void [12]. This procedure creates distress in the child, the parents, and occasionally staff [13–15]. Nonpharmacological methods to reduce this distress include education prior to the procedure, distraction during, and rewards after [14, 16–28].

Pharmacological interventions primarily focus on sedation but also could include beneficial analgesic, anxiolytic, and amnesic effects [29, 30]. Sedation brings with it cost, time, and safety concerns [1, 29–33]. It is unknown whether we can predict which children will go on to have distress or whether we should sedate routinely [34]. Which agents should we use, and what is the best route of administration? The majority of children having VCUG would not have had one previously. Coping styles and parent-child interaction are important determinants of distress during a medical procedure [34]. Safety of sedating agents is excellent in the context of a sedation service with the necessary staff and equipment to manage sedation in young children [35–37]. Those who sedate children should be prepared for inadvertent deeper sedation, basic life support, and airway management [29–31, 38–40]. Advanced help should be available. Time and cost factors limit the introduction of this distress-reducing intervention. Sedation recovery area and staff time are being the primary cost factors. The medications themselves are relatively inexpensive. Finally, are we sure that sedation does not influence the VCUGs ability to diagnose vesicoureteric reflux?

2. METHODS

These methods include a sensitive search of PubMed (1950–2007), EMBASE (1980–2007), Cochrane Database of Systematic Reviews, and Cochrane Randomised Controlled Trials Register. Articles on VCUG were identified through the terms urography (MESH heading exploded), micturating, or voiding cystourethrogram using wildcard search for variations of spelling. Acronyms VCUG and MCUG were also used. To identify sedation articles, the following exploded MESH terms were used: “hyponotics and
were considered to be of interest \[6, 8, 13, 14, 16, 41–52\].

EMBASE search found 416 papers of which additional 8 papers were of interest \[27, 35, 53–59\]. Cochrane Randomised Controlled Trials Register found no further articles of interest. Cochrane Database of Systematic Reviews found one review on interventions for primary vesicoureteric reflux, but none on sedation for this procedure \[7\]. A review of the bibliographies identified further 39 papers of interest \[2–5, 9, 11, 15, 17–22, 26, 28, 34, 37, 40, 60–81\]. Four papers on anesthesiology for VCUG were found and included for discussion \[82–85\].

Any study comparing a sedative against another sedative, placebo, or standard treatment for VCUG was reviewed. One French language article \[77\] and one Polish language article \[56\] were not included. Study designs are summarised in Table 1. Outcome measures and results are in Table 2 \[41, 43, 45, 47, 52, 59\]. Quality assessment is shown in Table 3. Only two of the studies \[45, 52\] were of high quality with Jadad scores \[86\] of 4 or more. One unpublished comparative study was found, but not included \[68\].

4. DISCUSSION

The best way to avoid the distress of the VCUG is not to do the procedure. A better way to image vesicoureteric reflux has recently been discussed in an editorial by Elder \[55\]. As much evidence becomes available to show that we are not influencing the outcome of VUR, less VCGs may be ordered \[7, 93\]. Possible alternatives include Doppler ultrasound \[94\] or ultrasound with contrast \[61\]. A suprapubic approach to avoid catheterisation seems promising but still requires filling and voiding \[49\]. Methods to detect reflux without voiding are impaired as some reflux may be present only on voiding \[95\], although the fact that whether this is important or not is debated \[96\]. Nuclear medicine scanning may be an alternative or may be able to select those who are more likely to benefit from VCUG \[67\]. Nuclear medicine cystoscopy replaces radio-opaque contrast with pharmacolabelled material with lower radiation, but otherwise it is very similar to the VCUG. Currently, VCUG remains the gold standard until less invasive tests are developed \[1\]. At the very least, we should be perfecting our current technique \[12\].

5. DISTRESS, PAIN, AND ANTICIPATORY ANXIETY

Distress is an all encompassing term that may or may not include a painful stimulus. This can be evidenced by fear of a procedure, pain responses prior to nociceptive stimuli, or anxiety behaviours before a planned event. Distress during the voiding cystourethrogram has been reported in observational and controlled studies. Phillips et al. \[13\] showed that 52 out of 73 children \(71\%\) experienced serious or severe distress, severe distress, or panic on the Groningen distress rating scale \[90\]. Herd et al. found that serious or severe distress was detected in 61% of all unsedated children at some stages during the VCUG. This level of distress may have been brief but is generally considered unacceptable. This distress is caused not only by urethral catheterisation, but also by the distension of the bladder and the subsequent voiding of urine in a socially abnormal situation (Figure 1). Nociceptors related to urethral mucosa and stretch receptors in the bladder provide the peripheral pain signals, but the majority of the distress is cortical.

Distress can also be manifest in the parent. Parents’ perceptions of fear, distress, and pain in their children are anticipated to be greater than the reality \[51\].

6. PSYCHOLOGICAL THERAPY (NONPHARMACOLOGICAL TREATMENTS)

Psychological treatments should be considered first as they often have little or no risk. There are many ways to reduce the distress of procedures in children \[19\] and even more challenges researching and implementing psychological interventions for controlling children’s pain \[97\]. Interventions may range between simple educational \[28\] and more structured play therapy sessions \[14, 76\] and hypnoses \[42\]. Preparation, distraction, and reassurance before, during, and after the procedure are likely to reduce the distress of the procedure \[22, 69, 75\]. Parental presence is comforting for children during painful procedure and should be encouraged despite the lack of specific VCUG evidence \[23\].
Table 1: Studies comparing a sedative against another sedative, placebo, or standard treatment for VCUG. Design and interventions. (NSD: no significant difference; VCUG: voiding cystourethrogram; RNC: radionuclide cystography; VUR: vesicoureteric reflux; SD: standard deviation).

<table>
<thead>
<tr>
<th>Authors; year; country</th>
<th>Title</th>
<th>Patients</th>
<th>Intervention and comparison</th>
<th>Nonpharmacological cointervention</th>
<th>Time of follow-up and differences (if any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Akil, M. Ozkol, O. Y. Ikizoglu, M. Polat, O. Y. Tuncyurek, O. Taskin, H. Yuksel; 2005; Turkey [41]</td>
<td>&quot;Premedication during micturating cystourethrogram to achieve sedation and anxiolysis&quot;</td>
<td>53 (39F;14M), &gt;6 m, median age of 6 y (range from 7 m to 11.1 y); first VCUG 98%</td>
<td>Oral midazolam of 0.6 mg/kg (max. of 15 mg) versus chloral hydrate of 25 mg/kg (max. of 500 mg) versus Placebo; 15–30 min prior to VCUG</td>
<td>Parents informed about MCUG and permission granted for sedative drug and making child nil by mouth for 3 h, parental presence not stated</td>
<td>Until they were allowed to drink clear liquids, usually 1 h after completion of the procedure</td>
</tr>
<tr>
<td>J. S. Elder, R. Longenecker; 1995; USA [43]</td>
<td>&quot;Premedication with oral midazolam for voiding cystourethrography in children: safety and efficacy&quot;</td>
<td>98 children previously distressed by VCUG (38) or appeared shy (79F;19M), mean age of 4.4 (range from 23 m to 9 y); 25 controls (21F:4M), mean age of 4.6 (range not stated); first VCUG 98%</td>
<td>Oral midazolam of 0.6 mg/kg (max. of 15 mg), 20–30 min prior to VCUG or NUC versus standard care</td>
<td>Parents of intervention group-contacted prior with purpose of midazolam and expected effects, parents are allowed to be present</td>
<td>Phone call at 48 h</td>
</tr>
<tr>
<td>D. W. Herd, K. A. McAnulty, N. A. Keene, D. E. Sommerville; 2006; New Zealand [45]</td>
<td>&quot;Conscious sedation reduces distress in children undergoing voiding cystourethrography and does not interfere with the diagnosis of vesicoureteric reflux: a randomized controlled study&quot;</td>
<td>Children of 1–14 y (eligible); 139 randomised, 117 completed VCUG on the day (84F:33M), 8 had VCUG completed later, age &gt;1 y, mean ages of 3.6 y (SD1.8) and 3.4 y (SD2.1), ASAI-II</td>
<td>Oral midazolam of 0.5 mg/kg (max. of 15 mg), 30 min prior to catheter insertion versus placebo</td>
<td>All offered play therapy (visit to department, doll catheterised), four-page pamphlet, only the treatment group fasted for 6 h with solids and 4 h with liquid (i.e., control group was allowed to eat), parent/caregiver present, skilled nurse did all catheters</td>
<td>60–90 min after medication</td>
</tr>
<tr>
<td>I. Keidan, R. Zaslansky, M. Weinberg, A. Ben-Shlush, J. M. Jacobson, A. Augarten, Y. Mor; 2005; Israel [47]</td>
<td>&quot;Sedation during voiding cystourethrography: comparison of the efficacy and safety of using oral midazolam and continuous flow nitrous oxide&quot;</td>
<td>47 (42F:5M), age of 3–16 y, ASAI and II, mean age of 6 (range from 3 to 15)</td>
<td>Oral midazolam of 0.5 mg/kg (max. of 15 mg), 20 min prior to procedure versus continuous flow 50% nitrous oxide</td>
<td>Both groups fasted with solids for 6 h, and liquids for 2 h, parents were encouraged to accompany the children throughout the procedure, flavoured nasal mask was used for nitrous oxide</td>
<td>24 h follow-up by telephone, recovery time of 63 min (SD 25) in midazolam group, 29 min (SD 10) in the N2O group (p &lt; .001)</td>
</tr>
<tr>
<td>P. A. Merguerian, S. T. Corbett, J. Cravero; 2006; USA [48]</td>
<td>&quot;Voiding ability using propofol sedation in children undergoing voiding cystourethrograms: a retrospective analysis&quot;</td>
<td>544 charts, 287 selected ages from 2 to 8 (preslected), mean age of 51 m (244F:43M), first VCUG 75%</td>
<td>Sevoflurane induction followed by propofol infusion on its own (historical controls)</td>
<td>Not reported</td>
<td></td>
</tr>
</tbody>
</table>
Those who have been previously distressed by VCUG would seem to be ideal candidates for sedation, but the majority of children would not have had a previous VCUG. Factors which may reduce distress in children during VCUG include “effortful control” by the child and coping and distress-promoting behaviours by the parent [34]. No validated prediction tool exists for VCUG distress.

7. PHARMACOTHERAPY

Pharmacotherapy includes sedation, anxiolysis, analgesia, amnesia, and anesthesia.

7.1. Sedating agents

Sedation continues to be difficult to define[63]. In the case of the VCUG, a degree of consciousness is required. This may be defined as light sedation, and the use of oxymoron “conscious sedation” is being discouraged [98].

**Midazolam**

Of the selected studies, 5 had midazolam as a treatment arm and 4 of which were oral and one intranasal. Oral midazolam dose was 0.5 mg/kg in two studies [45, 47] and 0.6 mg/kg in two other studies [41, 43]. Maximum dose was 15 mg in all. Time between ingestion and procedure ranged from 15 to 30 minutes. Intranasal dose in one study was 0.2 mg/kg with a maximum of 5 mg, and it was administered 5 minutes before the procedure [52]. A number of behavioural measures were employed (Table 1). All the studies demonstrate significantly less distress with midazolam in a variety of measurement tools. Few adverse effects were encountered. Midazolam may cause adverse paradoxical agitated reactions in less than 5% of children [99]. These reactions have been shown in case reports to be ameliorated using the antidote for midazolam (flumazenil) both in adults [100] and children [101]. Ketamine, a dissociative anesthetic, has been shown to be more effective than increased doses of midazolam or placebo in a randomised controlled trial [99].

The study by Stockland et al. [52] on 95 children compared intranasal midazolam (0.2 mg/kg with a maximum of 5 mg) to placebo. Nurses reported a trend to easier procedure in the midazolam group ($P = .07$), with girls reported easier than boys ($P = .06$). No serious adverse events were reported. Parents felt that the administration of midazolam was more uncomfortable than that of placebo ($P < .001$). Parents felt that midazolam made catheterisation, voiding, and the overall procedure more comfortable ($P = .015$, $P = .08$, and $P = .047$, resp.). The authors report $P$-values and no absolute scores, which makes it impossible to estimate treatment effect size or clinical relevance.

A study by the current author and colleagues [45] compared oral midazolam (0.5 mg/kg with a maximum of 15 mg) to placebo in 125 children who had VCUG. Behavioural observations were completed in 117. This was the only study that calculated a priori power requirement or attempted to quantify the treatment effect. We rated our paper highly using the Jadad score [86]. We found no serious adverse events. The number of children experiencing serious or severe distress (Grongingen distress rating scale (GRDS) $>2$) at any stage of the procedure was 34 (61%) in the placebo group and 16 (26%) in the midazolam group. Number needed to treat to reduce serious or severe distress in one child was 2.9 (95%CI 1.9–5.5). VUR was identified in 16% of all children. This study was limited to children above the age of one year.

### Table 1: Continued.

<table>
<thead>
<tr>
<th>Authors; year; country</th>
<th>Title</th>
<th>Patients</th>
<th>Intervention and comparison</th>
<th>Nonpharmacological cointervention</th>
<th>Time of follow-up and differences (if any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Stokland, S. Andrèasson, B. Jacobsson, U. Jodal, B. Ljung; 2003; Sweden [52]</td>
<td>“Sedation with midazolam for voiding cystourethrography in children: a randomised double-blind study”</td>
<td>Children of 0.5 to 9 y (eligible), 95 enrolled (70F: 20M), gender stratified, median age of 2.2 y, midazolam, 3.2 mg/kg placebo</td>
<td>Intranasal midazolam of 0.2 mg/kg (max. of 5 mg), 3–5 min prior to bladder catheter versus placebo</td>
<td>Oral and written information</td>
<td>Follow-up questionnaire and phone call at 48 h</td>
</tr>
<tr>
<td>J. L. Zier, K. A. Kvan, S. C. Kurachek, M. Finkelstein; 2007; USA [59]</td>
<td>“Sedation with nitrous oxide compared with no sedation during catheterization for urologic imaging in children”</td>
<td>Children of 4–18 y selected by investigator undergoing VCUG or RNC, enrolled 204 (165F : 39M) out of 389, mean age nonsedated: 6.4 (range of 4–15.2), sedated: 6.3 (range of 4–14.9)</td>
<td>Continuous flow 70% nitrous oxide until catheterisation is complete versus standard care</td>
<td>All patients fasted for 4 h</td>
<td>To time of discharge, longer in sedated group, 85 min versus 33 min ($P &lt; 0.001$)</td>
</tr>
</tbody>
</table>
Table 2: Studies comparing a sedative against another sedative, placebo, or standard treatment for VCUG. Outcomes, results, and follow-up. (NSD: no significant difference; VCU: voiding cystourethrogram; RNC: radionuclide cystography; VUR: vesicoureteric reflux; SD: standard deviation).

<table>
<thead>
<tr>
<th>Authors; year; country</th>
<th>Sedation score outcome and results</th>
<th>Distress outcome(s) and results</th>
<th>Urological outcome(s) and results</th>
<th>Safety outcome(s) and adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Akil, M. Ozkol, O. Y. Ikizoglu, M. Polat, O. Y. Tuncyurek, O. Taskin, H. Yuksel; 2005; Turkey [41]</td>
<td>Breitkopf and Buttner classification of emotional status [87], 1.87 (SD0.72) in midazolam versus 1.35 (SD0.49) in control (P = .01), duration of sedation is 68 min (midazolam), 28 min (chloral), P &lt; .001</td>
<td>Frankl behaviour rating score [88] NSD; Spielberger’s state anxiety inventory [41] NSD; Houpt behaviour scale [88] of 4.93 (SD1.12) in midazolam group versus control of 4.12 (SD 1.05) in chloral group, all NSD</td>
<td>Postvoid residual volume, VCU grading, no difference found</td>
<td>None found, defined as drop in PaO2/Sats by 5%, systolic blood pressure drop of 15 mm Hg, drop in pulse to 60 bpm</td>
</tr>
<tr>
<td>J. S. Elder, R. Longenecker; 1995; USA [43]</td>
<td>None</td>
<td>Phone call at 48 h, recall, behavioural side effects; parental wishes, 97 out of 98 contacted, 56 children (60%), no recall of VCUG, 19 (21%) recalled parts, 10 remembered the procedure without negative experience, 9 recalled a negative experience, 12 out of 97 children had behavioural side effects reported after the study, 92 out of 97 (95%) parents of sedated children would request the use of midazolam again</td>
<td>Postvoid residual volume (Bis and Slovis method [89]), no residual volume in 74% of midazolam group and 72% of control group; NSD</td>
<td>Saturation decrease by 10%, systolic BP drop by 15 mm Hg, respective rate down to 8/min, HR down to 60/min, one child had a transient decrease in saturation requiring no intervention</td>
</tr>
<tr>
<td>D. W. Herd, K. A. McAnulty, N. A. Keene, D. E. Sommerville; 2006; New Zealand [45]</td>
<td>None</td>
<td>Independent observer Groningen distress rating scale [90]; nursing GDRS; heart rate; parent-child interaction, 61% of placebo group experienced serious or severe distress (GDRS of 3 or 4); 26% of midazolam group had the same distress; number needed for treatment was 2.9 (95%CI 1.9–5.5)</td>
<td>VUR grade; volume infused, no difference in volume infused (P = .8), no difference in VUR grading (P = .31), a priori power of 90%</td>
<td>Oxygen requirement (Sats &lt;94%), two children in midazolam group had transient desaturations to less than 94% and were given oxygen</td>
</tr>
</tbody>
</table>

Nitrous oxide (N₂O)

Two studies evaluated nitrous oxide given with continuous flow devices at 50% and 70%. Keidan et al. compared 50% nitrous oxide in 23 children to 0.5 mg/kg oral midazolam in 24 children without a placebo group [47]. They found no difference between midazolam and 50% nitrous oxide although they did not design this as an equivalence study, and no power calculation was done. There was a trend for the time to micturition to be longer in the nitrous group.
Table 2: Continued.

<table>
<thead>
<tr>
<th>Authors; year; country</th>
<th>Sedation score outcome and results</th>
<th>Distress outcome(s) and results</th>
<th>Urological outcome(s) and results</th>
<th>Safety outcome(s) and adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Keidan, R. Zaslansky, M. Weinberg, A. Ben-Shluch, J. M. Jacobson, A. Augarten, Y. Mor; 2005; Israel [47]</td>
<td>AVPU (alert, responds to voice, responds to pain, unresponsive)</td>
<td>FLACC (face, legs, activity, crying, consolability) score for pain [91]; anxiety score (observer scale of behavioural distress) [92]; no difference between midazolam and nitrous oxide, number of children requiring physical restraint is 10/24 in midazolam and 2/23 for N2O ((P = .01))</td>
<td>Time to micturition 7.2 (SD 2.5) min for midazolam and 15.3 (SD 17.3), (P = .8)</td>
<td>Oxygen saturation &lt;93%, alteration in heart rate or BP by 15% from baseline, oversedation defined as “U” on the AVPU scale</td>
</tr>
<tr>
<td>P. A. Merguerian, S. T. Corbett, J. Cravero; 2006; USA [48]</td>
<td>Not reported</td>
<td>None</td>
<td>Void to completion; sedated children (55%) could void to completion compared to 89% nonsedated ((P &lt; .001))</td>
<td>Not reported</td>
</tr>
<tr>
<td>E. Stokland, S. Andréasson, B. Jacobsson, U. Jodal, B. Ljung; 2003; Sweden [52]</td>
<td>None</td>
<td>VAS from 0 mm to 100 mm (severe problems); nurse observation VAS NSD, parent VAS, administration of midazolam more uncomfortable ((P &lt; .001)), catheter, and overall procedure more uncomfortable with placebo ((P &lt; .001)); parent follow-up questionnaire at 12, 24, and 48 h of “reactions,” NSD</td>
<td>VUR grade; volume infused; ability to void; NSD</td>
<td>Not defined, none reported</td>
</tr>
<tr>
<td>J. L. Zier, K. A. Kram, S. C. Kurachek, M. Finkelstein; 2007; USA [59]</td>
<td>None</td>
<td>Brief behavioural distress score (BBDS) for VCUG, median age of 44 (range of 11–100) nonsedated, 11 (range of 0–67) sedated ((P &lt; .001)), patient self-reported Wong-Baker FACES pain rating scale, 6 after catheter in nonsedated, 0 in sedated ((P &lt; .001))</td>
<td>Time to bladder emptying; NSD</td>
<td>One patient in sedated group experienced nausea, no desaturations</td>
</tr>
</tbody>
</table>

(15.3 minutes versus 7.2 minutes), but it did not reach statistical significance (\(P = .08\)). Nitrous oxide was significantly faster with regard to recovery time, with recovery in 29 minutes versus 63 minutes (\(P < .001\)). Zier et al. used 70% continuous nitrous oxide only for urethral catheterisation phase of VCUG in an older group of 107 children, and compared this to standard treatment in other 107 children [59]. The authors chose not to randomise the study based on difficulties with recruitment and parental expectations. Brief behavioural distress scores (BBDSs) were demonstrated...
Table 3: Quality assessment of studies of sedation for VCUG, including Jadad score [86].

<table>
<thead>
<tr>
<th>Authors; year; country; reference</th>
<th>Randomised</th>
<th>Randomisation described</th>
<th>Blinded</th>
<th>Allocation concealment</th>
<th>Withdrawals and dropouts</th>
<th>Control</th>
<th>Placebo group</th>
<th>A priori power</th>
<th>Jadad score</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Akil, M. Ozkol, O. Y. Ikizoglu, M. Polat, O. Y. Tuncyurek, O. Taskin, H. Yuksel; 2005; Turkey [41]</td>
<td>Quasi</td>
<td>Y</td>
<td>Y (not described as double blind)</td>
<td>Cherry-flavoured liquid</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>1 (poor)</td>
</tr>
<tr>
<td>J. S. Elder, R. Longenecker; 1995; USA [43]</td>
<td>N</td>
<td>—</td>
<td>N</td>
<td>Kool-aid (artificial sweetner)</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>0 (poor)</td>
</tr>
<tr>
<td>D. W. Herd, K. A. McAnulty, N. A. Keene, D. E. Sommerville; 2006; New Zealand [45]</td>
<td>Y</td>
<td>Y</td>
<td>Y (blinding analysis done)</td>
<td>Mango and orange juices</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
<td>5 (excellent)*</td>
</tr>
<tr>
<td>I. Keidan, R. Zaslansky, M. Weinberg, A. Ben-Shlush, J. M. Jacobson, A. Augarten, Y. Mor; 2005; Israel [47]</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>—</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>1 (poor)</td>
</tr>
<tr>
<td>P. A. Merguerian, S. T. Corbett, J. Cravero; 2006; USA [48]</td>
<td>N</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Y (historical)</td>
<td>N</td>
<td>N</td>
<td>0 (poor)</td>
</tr>
<tr>
<td>E. Stokland, S. Andréasson, B. Jacobsson, U. Jodal, B. Ljung; 2003; Sweden [52]</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Described</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>4 (good)</td>
</tr>
</tbody>
</table>

*Authors' self-score.
by the observational tool selected [102]. Wong-Baker FACES scale was the self-report tool used [103]. For the VCUG group (n = 101), BBDS was 44 (range of 11–100) in the nonsedated group versus 11 (range of 0–67) for the sedated group (P < .001). Immediately after catheterisation, the Wong-Baker FACES scale median was 6 for the nonsedated group and 0 for the sedated group (P < .001). Both studies reported time of completion, but neither study reported VUR grading or residual volume.

Other agents

Choral hydrate was compared to oral midazolam and placebo in one study [41]. A dose of 25 mg/kg was not found to be statistically different from placebo in reducing distress. This may have been due to inadequate dose or lack of power in the study. The sedation scale was also not significant for chloral versus placebo and, therefore, it suggests too low a dose was selected. There is no enough data to make any assessment of effect on voiding dynamics.

One retrospective study of propofol using historical controls was selected for review [48]. While this was an attempt to create a sedative state using low-dose propofol, the study required the presence of an anesthetist. During this study, low-dose propofol infusion followed sevoflurane gas induction and intravenous cannula insertion. This study found that propofol reduced the ability of children to completely void, which may interfere with the diagnosis of VUR.

7.2. Anxiolysis

Midazolam in the doses used in the reviewed studies is anxiolytic. Many children may appear fully conscious yet more cooperative, while another child given the same dose may appear sleepy. Where anxiolysis ends and sedation begins is unclear, but there would be a large overlap.

7.3. Analgesia

There is a wide range of analgesics available for children [104]. Midazolam does not provide any analgesia and, therefore, should be supplemented with a simple analgesic.

Acetaminophen

Acetaminophen is the most commonly provided childhood analgesic with low side effects and cost. It is routinely offered prior to other potentially painful procedures in children such as vaccination. Acetaminophen is usually provided in a sweet syrup base, and could be used to disguise the bitter taste of midazolam. There are many formulations of acetaminophen syrup, and palatability may vary [105].

Oral sucrose

Oral sucrose is an effective analgesic in new-born babies, and has been subject to several controlled trials and a Cochrane review [106]. While no studies have examined its effect for VCUG distress, it seems a simple likely effective intervention with low risk for children under 3 months of age.

Nitrous oxide

Nitrous oxide is a strong analgesic antagonising central NMDA receptors, and this is a potential advantage over midazolam. Study of Keidan et al. comparing midazolam to continuous flow nitrous oxide found no difference in FLACC scores [91], a measure of pain used more recently for procedural distress [107]. Study of Keidan et al. was not designed as an equivalence study, and no power calculations were done; so a true difference may not have been detected by the study.

Opiates

No studies have looked at opiate use for VCUG distress. Intranasal midazolam has proven effective, and opiates may also be administered by this route. Intranasal fentanyl shows promise as a rapid, easy-to-administer analgesic for severe pain in the children’s Emergency Department [108]. Opiates may interfere with bladder function [109].

Local anesthetics

Lignocaine gel has been shown to reduce the pain of catheterisation for VCUG, but a 10-minute process of repeated application of lignocaine gel to the urethral meatus is required. The authors did not measure the effect of this procedure but only the reduced pain of catheterisation that followed. It would seem reasonable to use it with low risk of harm but at added cost [66]. Further study on children is required.

7.4. Anesthesia

There is increasing use of deeper sedation outside the operating room by nonanesthesiologists [110]. There is debate about which agents should be used outside the operating room and who should provide this service [63]. For VCUG, anesthetics have been given to avoid the trauma associated with urethral catheterisation, and then the child is allowed to wake and complete the VCUG. This does not avoid the distress caused by bladder distension or micturition. It also requires an anesthetist and the full costs associated with anesthesia and recovery.

8. WHO SHOULD RECEIVE SEDATION?

Many children do not experience distress during the VCUG. This may be related to previous experience, coping style, parental influence, staff skill, and empathy. Developmental considerations and education level of the child and parent are important. Nevertheless, many children, who would not have been predicted, may go on to experience distress. Parental perceptions of the procedure are such that most parents would request some medication if it were effective, safe, and available [43, 47].
9. DOES SEDATION AFFECT THE ABILITY OF THE VCU TO DIAGNOSE REFUX?

Effect of sedation on ability to void can be measured with indirect or direct measures. Indirect measures include filling volume, residual volume, and time of micturition. Bozkurt et al. carefully examined urodynamic variables under the influence of midazolam [62]. They used a high-intranasal dose of 0.5 mg/kg. Stockland et al. used intranasal midazolam at a dose of 0.2 mg/kg, and found no difference in reflux grading between the groups [52]. They did not perform a power calculation, so there is still the possibility of missing a true effect. Herd et al. considered a clinically important difference in VUR to be a true shift of one grade down by half of the subjects with the use of midazolam [45]. It was important to detect a difference, so a 90% power was used. There was no difference in VUR grading between the groups (nonlinear mixed model analysis, \( P = .31 \)). There was no evidence of a difference in volume infused between the two groups (\( P = .8 \)).

10. CONCLUSIONS

Sedation reduces distress of the micturating cystourethrogram in children previously distressed or likely to be distressed. Midazolam is the agent most studied, and has an excellent safety profile. An oral dose of 0.5-0.6 mg/kg or intranasal dose of 0.2 mg/kg seems effective. Most children have not had a VCUG previously, and it may be difficult to predict which of them will go on to have distress. When giving oral midazolam of 0.5 mg/kg to children routinely, the number needed to treat them is 2.9 (95% CI 1.9–5.5) to eliminate serious or severe distress. Continuous flow nitrous oxide appears promising, particularly with a fast onset and recovery time, but it has greater potential for deeper sedation. This may interfere with voiding, and further studies are required. Midazolam appears not to interfere with the VCUG’s ability to diagnose vesicoureteric reflux using indirect (residual volume) and direct (VUR grading) measures. There are many children who would avoid distress if they were given sedation. Local sedation services should be engaged, and safety guidelines should be followed to ensure that this effective treatment might be implemented safely.

ACKNOWLEDGMENT

A grant from the Waikato Medical Research Foundation for the original VCU sedation study made this review possible.

REFERENCES


